Harvard Apparatus Regenerative Technology Inc.

OTCPK:HRGN Stock Report

Market Cap: US$47.3m

Harvard Apparatus Regenerative Technology Valuation

Is HRGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HRGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate HRGN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate HRGN's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HRGN?

Key metric: As HRGN barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for HRGN. This is calculated by dividing HRGN's market cap by their current book value.
What is HRGN's PB Ratio?
PB Ratio12.4x
BookUS$3.84m
Market CapUS$47.28m

Price to Book Ratio vs Peers

How does HRGN's PB Ratio compare to its peers?

The above table shows the PB ratio for HRGN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average13.8x
TNXP Tonix Pharmaceuticals Holding
0.5x9.3%US$35.9m
KRON Kronos Bio
0.5x5.9%US$53.6m
AURX Nuo Therapeutics
53.4xn/aUS$47.5m
GBIO Generation Bio
0.9x11.5%US$93.5m
HRGN Harvard Apparatus Regenerative Technology
12.4xn/aUS$47.3m

Price-To-Book vs Peers: HRGN is good value based on its Price-To-Book Ratio (12.4x) compared to the peer average (13.8x).

Price to Book Ratio vs Industry

How does HRGN's PB Ratio compare vs other companies in the US Biotechs Industry?

59 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$594.06m
AMRN Amarin
0.4x-7.7%US$217.60m
IMAB I-Mab
0.4x1.8%US$76.61m
MGX Metagenomi
0.3x-23.2%US$75.22m
HRGN 12.4xIndustry Avg. 1.9xNo. of Companies78PB01.63.24.86.48+
59 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: HRGN is expensive based on its Price-To-Book Ratio (12.4x) compared to the US Biotechs industry average (1.9x).

Price to Book Ratio vs Fair Ratio

What is HRGN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HRGN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio12.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate HRGN's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$57.86

7D

3.9%

1Y

15.0%

Teva Pharmaceutical Industries

US$18.9b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.59

7D

-1.3%

1Y

69.3%

Collegium Pharmaceutical

US$993.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$31.19

7D

4.8%

1Y

22.3%